322 related articles for article (PubMed ID: 17973542)
21. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study.
Zannas AS; Okuno Y; Doraiswamy PM
Pharmacotherapy; 2014 Mar; 34(3):272-8. PubMed ID: 24127392
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
23. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
24. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.
Sadowsky C; Perez JA; Bouchard RW; Goodman I; Tekin S
CNS Neurosci Ther; 2010; 16(1):51-60. PubMed ID: 20070789
[TBL] [Abstract][Full Text] [Related]
25. Drug interactions related to self-medication: a French pharmacovigilance database study.
Vacher R; Lagarce L; Ghamrawi S; Laugier-Castellan D; Vial T; Bagheri H; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Oct; 34(5):623-631. PubMed ID: 32064672
[TBL] [Abstract][Full Text] [Related]
26. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.
Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
Fundam Clin Pharmacol; 2014 Apr; 28(2):230-5. PubMed ID: 23190210
[TBL] [Abstract][Full Text] [Related]
27. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
28. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
[TBL] [Abstract][Full Text] [Related]
29. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
Kröger E; Berkers M; Carmichael PH; Souverein P; van Marum R; Egberts T
Am J Geriatr Pharmacother; 2012 Dec; 10(6):373-80. PubMed ID: 23217530
[TBL] [Abstract][Full Text] [Related]
30. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
Danton AC; Montastruc F; Sommet A; Durrieu G; Bagheri H; Bondon-Guitton E; Lapeyre-Mestre M; Montastruc JL
Eur J Clin Pharmacol; 2013 Apr; 69(4):885-8. PubMed ID: 22996074
[TBL] [Abstract][Full Text] [Related]
31. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
32. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
33. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
[TBL] [Abstract][Full Text] [Related]
34. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
[TBL] [Abstract][Full Text] [Related]
35. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
Ritchie CW; Ames D; Clayton T; Lai R
Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
[TBL] [Abstract][Full Text] [Related]
36. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
39. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
Herrmann N; Binder C; Dalziel W; Smyth S; Camacho F
Drugs Aging; 2009; 26(5):403-7. PubMed ID: 19552492
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
